Hutchison China Meditech Ltd (HCM)

 

HCM Share PerformanceMore

52 week high4,580.00 16/10/17
52 week low1,810.00 25/10/16
52 week change 2,655.00 (145.88%)
4 week volume263,474 22/09/17

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

Chi-Med and AZ present encouraging data on lung cancer drug

Hutchison China Meditech has announced that savolitinib - the lung cancer drug being developed in collaboration with As...

Savolitinib Shows Encouraging Clinical Activity

RNS Number: 7831T Hutchison China Meditech Limited 17 October 2017 Chi-Med and AstraZeneca's Savolitinib Shows Encouraging Clinical Activity in Second-Line EGFR Mutation-Positive Lung Cancer with MET -Amplification - Data for savolitinib in combination with Tagrisso or Iressa presented at World Conference on Lung Cancer- - New data give insights in...

Chi-Med reports 'promising data' on lung cancer drug

Hutchison China MediTech has reported preliminary clinical activity, safety, and tolerability data of fruquintinib, an inve...

Chi-Med Reports Preliminary Phase II data

RNS Number: 6323T Hutchison China Meditech Limited 16 October 2017 Press Release Chi-Med Reports Preliminary Phase II data on Fruquintinib Combination in First-Line Lung Cancer - Fruquintinib in combination with Iressa (gefitinib) shows promising efficacy and an acceptable safetyprofile- - Further validation of strong potential for use of fruquintinib in co...

Appointment of Director

RNS Number: 4095T Hutchison China Meditech Limited 12 October 2017 Appointment of Director London: Thursday, October 12, 2017: Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) today announces that Professor Mok, Shu Kam Tony has been appointed as Independent Non-Executive Director and member of the Technical Committee with...

Best AIM companies of 2017

The annual AIM Awards are almost upon us, so former AIM writer of the year Andrew Hore names the small-cap compa...

Savolitinib and Fruquintinib presentations at WCLC

RNS Number: 2064S Hutchison China Meditech Limited 29 September 2017 Press Release Chi-Med to Present Savolitinib and Fruquintinib Clinical Data at WCLC 2017 Annual Meeting - Data to show potential of savolitinib to treat EGFR-TKI resistance in both Iressa and Tagrisso refractory patients with MET amplification- - Results to further validate Chi-Med's scien...

Oral Presentations at CSCO Annual Meeting

RNS Number: 2058S Hutchison China Meditech Limited 29 September 2017 Press Release Chi-Med Highlights Oral Presentations at CSCO Annual Meeting - Three oral presentations given at CSCO for fruquintinib, savolitinib and theliatinib- - Plenary keynote presentation for FRESCO Phase III trial details analysis showing consistent survival benefit in all key subgrou...

Latest discussion posts More

  • London Eveniong Standard

    Lead article in today's London Evening standard https://www.standard.co.uk/business/anthony-hilton-the-remarkable-tale-of-chimed-s-growth-a3661656.html Mr Hilton has ...
    18-Oct-2017
    David Global
  • Re: Slater Growth Fund Holding

    September's data shows HCM at 10.33% of his growth fund. http://www.slaterinvestments.com/media/108554/slater_growth_fund_a_-_fact_sheet_september_2017.pdf Given it was ...
    18-Oct-2017
    Boring Bernie
  • Re: Savolitinib and Tagrisso

    when it was what? between 1200 and 2000p? I notice Canaccord, Stifel and Panmure keep upgrading their price targets as the Company smashes them!
    18-Oct-2017
    David Global

Users' HoldingsMore

Users who hold Hutchison China Meditech Ltd also hold..
GLAXOSMITHKLINE21%
RDS 'B'21%
LLOYDS GRP.20%
NATIONAL GRID17%
VODAFONE GRP.16%

Codes & Symbols

ISINKYG4672N1016
SymbolsHCM, LSE:HCM, HCM.L, HCM:LN, LON:HCM, XLON:HCM